AIDS and Behavior

, Volume 17, Issue 2, pp 585–597 | Cite as

Characteristics of Female Sex Workers in Southern India Willing and Unwilling to Participate in a Placebo Gel Trial

  • Barbara S. Mensch
  • Barbara A. Friedland
  • Sharon A. Abbott
  • Lauren L. Katzen
  • Waimar Tun
  • Christine A. Kelly
  • Avina Sarna
  • Aylur K. Srikrishnan
  • Suniti Solomon
Original Paper

Abstract

Respondent-driven sampling was used to recruit female sex workers (FSWs) for a community survey conducted in southern India. After survey completion, participants were given a brochure describing a clinical trial that entailed daily use of a placebo vaginal gel for four months. This study assessed predictors of screening among survey respondents, predictors of enrollment among those eligible for the trial, and predictors of visit attendance and retention among those enrolled. FSWs who reported having symptoms of sexually transmitted infections (STI), engaging in sex work in the past month, and living in a subdistrict easily accessible by public transportation with a high concentration of FSWs, were more likely to screen. FSWs who had never been tested for HIV were more likely to enroll. This analysis suggests that the primary reason FSWs participated in the trial was a desire for health care—not other factors hypothesized to be important, e.g., HIV risk perception and poverty status.

Keywords

Microbicides Willingness to participate Female sex workers Southern India 

References

  1. 1.
    Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedCrossRefGoogle Scholar
  2. 2.
    Hendrix CW, Minnis A, Guddera V, et al. MTN-001: a Phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. Conference on retroviruses and opportunistic infections; Boston, 2011.Google Scholar
  3. 3.
    Dhalla S, Poole G. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care. 2011;23(11):1430–47.PubMedCrossRefGoogle Scholar
  4. 4.
    Bartholow BN, MacQueen KM, Douglas JM Jr, Buchbinder S, McKirnan D, Judson FN. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr. 1997;16(2):108–15.CrossRefGoogle Scholar
  5. 5.
    Celentano DD, Beyrer C, Natpratan C, et al. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS. 1995;9:1079–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Giocos G, Kagee A, Swartz L. Predicting hypothetical willingness to participate (WTP) in a future phase III HIV vaccine trial among high-risk adolescents. AIDS Behav. 2008;12(6):842–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Jackson DJ, Martin HL Jr, Bwayo JJ, et al. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS. 1995;9:1279–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Jenkins RA, Chinaworapong S, Morgan PA, et al. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr. 1998;18:171–7.CrossRefGoogle Scholar
  9. 9.
    Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785–93.PubMedCrossRefGoogle Scholar
  10. 10.
    MacQueen KM, Vanichseni S, Kitayaporn D, et al. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1999;21:243–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Newman PA, Duan N, Roberts KJ, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr. 2006;41(2):210–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Suhadev M, Nyamathi AM, Swaminathan S, et al. A pilot study on willingness to participate in future preventive HIV vaccine trials. Indian J Med Res. 2006;124:631–40.PubMedGoogle Scholar
  13. 13.
    Sahay S, Mehendale S, Sane S, et al. Correlates of HIV vaccine trial participation: an Indian perspective. Vaccine. 2005;23:1351–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Strauss RP, Sengupta S, Kegeles S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three US communities. J Acquir Immune Defic Syndr. 2001;26:63–71.PubMedGoogle Scholar
  15. 15.
    Thapinta D, Jenkins RA, Morgan PA, et al. Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2002;30:503–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Vanichseni S, Tappero JW, Pitisuttithum P, et al. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX® B/E HIV vaccine tial, Bangkok, Thailand. AIDS. 2004;18:311–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Koblin B, Holte S, Lenderking B, Heagerty P, For the HIVNET vaccine preparedness study protocol team. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. J Acquir Immune Defic Syndr. 2000;24(5):451–7.PubMedGoogle Scholar
  18. 18.
    deSouza L, Munday PE. Audit of HIV partner notification in a district general hospital. Int J STD AIDS. 2003;14:854–5.CrossRefGoogle Scholar
  19. 19.
    Suhadev M, Nyamathi AM, Swaminathan S, Suresh A, Venkatesan P. Factors associated with willingness to participate in HIV vaccine trials among high-risk populations in south India. AIDS Res Hum Retrovir. 2009;25(2):217–24.PubMedCrossRefGoogle Scholar
  20. 20.
    Tarimo EA, Thorson A, Bakari M, Mwami J, Sandstrom E, Kulane A. Willingness to volunteer in a phase I/II HIV vaccine trial: a study among police officers in Dar es Salaam, Tanzania. Glob Health Action. 2009;2:1–7.Google Scholar
  21. 21.
    Ruzagira E, Wandiembe S, Bufumbo L, et al. Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda. Trop Med Int Health. 2009;14(2):196–203.PubMedCrossRefGoogle Scholar
  22. 22.
    Aliyu G, Mohammad M, Saidu A, et al. HIV infection awareness and willingness to participate in future HIV vaccine trials across different risk groups in Abuja, Nigeria. AIDS Care. 2010;22(10):1277–84.PubMedCrossRefGoogle Scholar
  23. 23.
    Etcheverry MF, Lum PJ, Evans JL, et al. HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco. Vaccine. 2011;29(10):1991–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Fincham D, Kagee A, Swartz L. Inhibitors and facilitators of willingness to participate (WTP) in an HIV vaccine trial: construction and initial validation of the Inhibitors and facilitators of willingness to participate scale (WPS) among women at risk for HIV infection. AIDS Care. 2010;22(4):452–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Tharawan K, Manopaiboon C, Ellertson C, et al. Women’s willingness to participate in microbide trials in northern Thailand. J Acquir Immune Defic Syndr Hum Retrovirol. 2001;28(2):180–6.Google Scholar
  26. 26.
    Gross M, Buchbinder SP, Celum C, Heagerty P, Seage GR III. Team ftHPSP. Rectal microbicides for U.S. gay men: are clinical trials needed? Are they feasible? Sex Transm Dis. 1998;25(6):296–302.PubMedCrossRefGoogle Scholar
  27. 27.
    Guest G, Severy L, von Mollendorf C, Van Damme L. Overcoming recruitment challenges: lessons learned from a safety and feasibility study of a diaphragm/microbicide combination in South Africa (Letter to the Editor). J Acquir Immune Defic Syndr. 2007;45(4):481–2.PubMedCrossRefGoogle Scholar
  28. 28.
    Ma M, Kibler JL, Vigil-Otero A, Sarpong D, Lally M, Mayer KH. Correlates of willingness to participate in microbicide research among African Americans. J Health Psychol. 2012; Feb 24 [Epub ahead of print].Google Scholar
  29. 29.
    van de Wijgert J, Coetzee N, de Kock A, Blanchard K, Jones H. Assessing selection bias in a microbicide trial. Poster presentation at the international congress of sexually transmitted infections—ISSTDR/IUSTI, Berlin,June 2001.Google Scholar
  30. 30.
    Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Aquir Immune Defic Syndr. 2004;36(1):604–12.CrossRefGoogle Scholar
  31. 31.
    NACO. HIV Sentinel Surveillance and HIV Estimation in India 2007: a technical brief. New Delhi: National AIDS Control Organisaion, Ministry of Health and Family Welfare, Government of India. October 2008.Google Scholar
  32. 32.
    NACO. HIV Fact Sheets: based on HIV Sentinel Surveillance Data in India 2003–2006. New Delhi: National AIDS Control Organisation, Ministry of Health and Family Welfare. November 2007.Google Scholar
  33. 33.
    Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005;19(Suppl 2):S67–72.PubMedCrossRefGoogle Scholar
  34. 34.
    Abdul-Quader AS, Heckathorn DD, Sabin K, Saidel T. Implementation and analysis of respondent driven sampling: lessons learned from the field. J Urban Health. 2006;83(Suppl 7):i1–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Tun W, Sarna A, Apicella L, Bhattacharya A. Recruitment of injecting drug users in two cities in India using respondent driven sampling for an HIV-related behavioral survey. In: 2nd international conference on surveying health in complex situations, 4 June 2007, University of Louvain, Belgium.Google Scholar
  36. 36.
    Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174–99.CrossRefGoogle Scholar
  37. 37.
    Heckathorn DD, Semaan S, Broadhead RS, Hughes JJ. Extensions of respondent-driven sampling: a new approach to the study of injection drug users aged 18–25. AIDS Behav. 2002;6(1):55–67.CrossRefGoogle Scholar
  38. 38.
    Tun W, Katzen LL, Abbott SA, et al. Using a 2-stage strategy with respondent-driven sampling to recruit a hard-to-reach population for a placebo microbicide gel clinical trial in Nellore, Andhra Pradesh (India). 2011. Unpublished.Google Scholar
  39. 39.
    Abbott SA, Friedland BA, Sarna A, et al. An evaluation of methods to improve the reporting of adherence in a placebo gel trial in Andhra Pradesh, India. 2011. Unpublished.Google Scholar
  40. 40.
    Filmer D, Pritchett LH. Estimating wealth effects without expenditure data, or tears: an application to educational enrollments in states of India. Demography. 2001;38(1):115–32.PubMedGoogle Scholar
  41. 41.
    Woodsong C, Alleman P, Musara P, et al. Preventive misconception as a motivation for participation and adherence in microbicide trials: evidence from female participants and male partners in Malawi and Zimbabwe. AIDS Behav. 2011. doi:10.1007/s10461-011-0027-7.
  42. 42.
    Microbicide Trials Network (MTN). Expanded safety and acceptability study of a non-medicated intravaginal ring. Microbicide trials network. http://www.mtnstopshiv.org/studies/72. Accessed 30 March 2012.
  43. 43.
    Coetzee N, Blanchard K, Ellertson C, Hoosen AA, Friedland B. Acceptability and feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides. AIDS. 2001;15(14):1837–42.PubMedCrossRefGoogle Scholar
  44. 44.
    Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977–87.PubMedCrossRefGoogle Scholar
  45. 45.
    Mensch BS, Hewett PC, Abbott S, et al. Assessing the reporting of adherence and sexual activity in a simulated microbicide trial in South Africa: an interview mode experiment using a placebo gel. AIDS Behav. 2011;15(2):407–21.PubMedCrossRefGoogle Scholar
  46. 46.
    FHI. FHI statement on the FEM-PrEP HIV prevention study http://minilicious.wordpress.com/2011/04/18/fhi-statement-on-the-fem-prep-hiv-prevention-study. Accessed 20 July 2011.
  47. 47.
    Microbicide Trials Network (MTN). MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. http://www.mtnstopshiv.org/node/3619 .Accessed 14 Oct 2011.
  48. 48.
    Thigpen MC, Kaebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Presentation given at international AIDS society conference, 17–20 July 2011, Rome. Oral abstract WELBC01.Google Scholar
  49. 49.
    Baeten J, Celum C, on behalf of the partners PrEP study team. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. Presentation given at International AIDS Society conference. 17–20 July 2011, Rome. Oral Abstract MOAX0106.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Barbara S. Mensch
    • 1
  • Barbara A. Friedland
    • 1
  • Sharon A. Abbott
    • 1
  • Lauren L. Katzen
    • 1
  • Waimar Tun
    • 2
  • Christine A. Kelly
    • 1
  • Avina Sarna
    • 3
  • Aylur K. Srikrishnan
    • 4
  • Suniti Solomon
    • 4
  1. 1.Population CouncilNew YorkUSA
  2. 2.Population CouncilWashingtonUSA
  3. 3.Population CouncilNew DelhiIndia
  4. 4.Y.R. Gaitonde Center for AIDS Research and Care (YRG CARE)ChennaiIndia

Personalised recommendations